Korean J Pediatr Infect Dis.  2012 Aug;19(2):55-60.

Immunoassay of Pertussis According to Ages

• Lee SY
• Choi UY
• Kim JS
• Ahn JH
• Choi JH
• Ma SH
• Park JS
• Kim HM
• Kang JH

Abstract

PURPOSE
We conducted the immunoassay of pertussis according to ages, in order to evaluate protective immunity against pertussis in Korean populations.
METHODS
Healthy subjects were enrolled at four university hospitals in Korea. The subjects were grouped as seven age groups (every 10 years). Antibodies against pertussis toxin (PT) in sera were measured by enzyme linked immunosorbent assay (ELISA) kits. Geometric mean concentrations (GMC) of antibodies and the ratios of the subjects with seroprotective antibody levels were determined. The subjects with antibody titers > or =24.0 EU/mL were considered to seroprotective as the manufacturer's protocol.
RESULTS
Total 1,605 subjects (age: 2 months-65 years) participated in this study, and their GMC was 56.16+/-50.54 EU/mL. Among seven age groups, age group <11 year showed the highest GMC (64.78+/-53.24 EU/mL) (P<0.001). In the analysis of the ratios of the subjects with seroprotective antibody titers, 68.2% of the subjects were proven to seroprotective, and age group <11 year also showed the highest ratio (76.5%) (P<0.001).
CONCLUSIONS
We found that adolescences or adults (age group > or =11 year) showed lower levels of antibody against pertussis and lower ratio of the subjects with seroprotective antibody titers than children (age group <11 year).

Keyword

Pertussis; Immunoassay; Immunization; Booster

MeSH Terms

Adult
Antibodies
Child
Enzyme-Linked Immunosorbent Assay
Hospitals, University
Humans
Immunization
Immunoassay
Korea
Pertussis Toxin
Whooping Cough
Antibodies
Pertussis Toxin

Figure

• 

  Fig. 1 Geometric mean concentrations (GMC) of subjects' antibodies against pertussis toxin (PT) are shown by age group and sex. (A) Adolescents and adults, and (B) children. Data of the past study performed in 200214) are also shown to compare the differences.

Reference

1. Cherry JD, Heininger U. Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, editors. Pertussis and other Bordetella infections. Feigin and Cherry's textbook of pediatric infectious diseases. 2009. 6th ed. Philadelphia: Saunders Co;1683–1706.

2. The Korean Pediatric Society. Lee HJ, editor. Diphtheria, pertussis, tetanus vaccines. Immunization guideline. 2008. 6th ed. Seoul: The Korean Pediatric Society;75–90.

3. Sato Y, Sato H. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children. Dev Biol Stand. 1985. 61:367–372.

4. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996. 334:341–348.

5. Liese JG, Meschievitz CK, Harzer E, Froeschle J, Hosbach P, Hoppe JE, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J. 1997. 16:1038–1044.

6. Hewlett EL, Edwards KM. Clinical practice. Pertussis-not just for kids. N Engl J Med. 2005. 352:1215–1222.

7. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005. 24:S25–S34.

8. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006. 55(RR-3):1–34.

9. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005. 24:S10–S18.

10. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed). 1988. 296:612–614.

11. Domínguez A, Vidal J, Plans P, Salleras L. The seroepidemiology of B. pertussis infection in Catalonia, Spain. Epidemiol Infect. 2001. 126:205–210.

12. Kim HH, Shin KH, Kim SN, Lee MS, Yoo SH, Kim JY, et al. Investigation on the immunity to pertussis in the Korea. J Korean Soc Microbiol. 1999. 34:583–589.

13. Kang JH, Hur JK, Kim JH, Lee KI, Park SE, Ma SH. Age related seroepidemiological study to tetanus and pertussis in Korean population. Annu Rep Korea Food Drug Adm. 2001.

14. Kang JH, Hur JK, Kim JH, Lee KI, Park SE, Ma SH. Age related seroepidemiological study to pertussis via standardization of perussis immunoassay among Koreans. Annu Rep Korea Food Drug Adm. 2002.

15. Jung SO, Moon YM, Sung HY, Kang YH, Yu JY. Serotype variations of agglutinogen and fimbriae in the Korean isolates of Bordetella Pertussis. Korean J Microbiol. 2008. 44:221–227.

16. Reizenstein E, Hallander HO, Blackwelder WC, Kühn I, Ljungman M, Möllby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods. 1995. 183:279–290.

17. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001. 20:63–75.

18. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001. 32:1691–1697.